Kamada (NASDAQ:KMDA – Get Free Report) and Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings.
Insider and Institutional Ownership
20.4% of Kamada shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 36.1% of Kamada shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Kamada and Ionis Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kamada | $180.46 million | 2.58 | $20.20 million | $0.43 | 18.81 |
| Ionis Pharmaceuticals | $944.00 million | 5.13 | -$381.39 million | ($3.32) | -8.75 |
Kamada has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Kamada and Ionis Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kamada | 12.67% | 9.36% | 6.53% |
| Ionis Pharmaceuticals | -56.98% | -120.62% | -16.99% |
Risk and Volatility
Kamada has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Kamada and Ionis Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kamada | 0 | 0 | 4 | 0 | 3.00 |
| Ionis Pharmaceuticals | 1 | 3 | 19 | 0 | 2.78 |
Kamada presently has a consensus target price of $13.75, suggesting a potential upside of 69.96%. Ionis Pharmaceuticals has a consensus target price of $75.71, suggesting a potential upside of 160.54%. Given Ionis Pharmaceuticals’ higher probable upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Kamada.
Summary
Kamada beats Ionis Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Kamada
Kamada Ltd. is an Israeli biopharmaceutical company that develops, manufactures and markets plasma-derived therapies and specialty pharmaceutical products. Founded in 1990, the company is headquartered in Rehovot, Israel. Its products include Glassia, an alpha-1 proteinase inhibitor used to treat people with alpha-1 antitrypsin deficiency, and immune globulin therapies for conditions including rabies exposure, cytomegalovirus infection and varicella-zoster exposure. Kamada serves markets in the United States and internationally, selling products directly and through commercial partners.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.
